Clinical Trial

ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer

Study acronym: EUROPA
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Rationale and relevance for patients and the scientific community. In low risk early stage patients ≥70 years, exclusive radiation therapy (RT) approach might be superior in terms of Health-Related Quality of Life (HRQoL), when compared to exclusive endocrine therapy (ET) following breast-conserving surgery (BCS). Assuming an equal rate of disease control, unnecessary long-term toxicity of ET may be avoided.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2019-10-18; most recent amendment 2025-08-25.
Status change: Recruiting → Active, Not Recruiting 2025-08-25
Status change: Not Yet Recruiting → Recruiting 2021-01-06
Trial Details
NCT Number NCT04134598
Lead Sponsor Azienda Ospedaliero-Universitaria Careggi
Collaborators: University of Florence
Conditions Breast Cancer
Enrollment 926 participants
Start Date 2021-02-08
Primary Completion 2030-03-31 (estimated)
Study Completion 2030-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-29